Paula A Schneider
Overview
Explore the profile of Paula A Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A, et al.
Mol Cancer
. 2024 Oct;
23(1):224.
PMID: 39375715
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer...
2.
Guru Murthy G, Saliba A, Szabo A, Harrington A, Abedin S, Carlson K, et al.
Haematologica
. 2024 Apr;
109(9):2864-2872.
PMID: 38572562
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of...
3.
Jia J, Ji W, Saliba A, Csizmar C, Ye K, Hu L, et al.
Cell Death Differ
. 2024 Mar;
31(4):405-416.
PMID: 38538744
BH3 mimetics, including the BCL2/BCLX/BCLw inhibitor navitoclax and MCL1 inhibitors S64315 and tapotoclax, have undergone clinical testing for a variety of neoplasms. Because of toxicities, including thrombocytopenia after BCLX inhibition...
4.
Al-Kali A, Aldoss I, Atherton P, Strand C, Shah B, Webster J, et al.
Cancer Med
. 2023 Nov;
12(23):21229-21239.
PMID: 37960985
Background: Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK-228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL....
5.
Correia C, Maurer M, McDonough S, Schneider P, Ross P, Novak A, et al.
Blood Cancer J
. 2023 May;
13(1):81.
PMID: 37193683
How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study demonstrating the early transformation of FLs...
6.
Saliba A, Kaufmann S, Stein E, Patel P, Baer M, Stock W, et al.
Blood Adv
. 2022 Oct;
7(11):2360-2363.
PMID: 36315007
No abstract available.
7.
Wahner Hendrickson A, Visscher D, Hou X, Goergen K, Atkinson H, Beito T, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885153
The poly(ADP-ribose) binding protein CHFR regulates cellular responses to mitotic stress. The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer. Despite...
8.
Schroeder B, Steen T, Espinoza I, Venkatapoorna C, Hu Z, Silva F, et al.
Cell Death Dis
. 2021 Oct;
12(11):977.
PMID: 34675185
Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted cancer therapies. However, little is known about the molecular determinants...
9.
Hurley R, McGehee C, Nesic K, Correia C, Weiskittel T, Kelly R, et al.
NAR Cancer
. 2021 Jul;
3(3):zcab028.
PMID: 34316715
Acquired PARP inhibitor (PARPi) resistance in - or -mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. is a less commonly studied ovarian cancer susceptibility...
10.
Ding H, Vincelette N, McGehee C, Kohorst M, Koh B, Venkatachalam A, et al.
Cancer Res
. 2021 Jan;
81(10):2666-2678.
PMID: 33414171
Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the...